JUN 2 4 2002

FIRM A PRADEMARY ON IN

Atty. Docket No.:

17633/1082

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Tongwen Wang

Serial No.:

09/927,738

Filed:

August 10, 2001

Entitled:

Compositions and methods for

modulating TGF-beta signaling

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

7298

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Kathleen Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents Washington, D.C. 20231

RECEIVED

TRANSMITTAL LETTER

JUN 2 6 2002

Enclosed for filing in the above-identified patent application, please find the 1600/2900 documents:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449
- 3. Copies of Cited References; and
- 4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 17633/1082. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Name: Kathleen Williams Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.:

17633/1082

PATENT

UNITED STATES PATENT AND TRADEMARK OFFICE

application of:

Tongwen Wang

Serial No.:

09/927,738

Filed:

August 10, 2001

Entitled:

Compositions and methods for

modulating TGF-beta signaling

Examiner:

Not Yet Assigned

RECEIVED

Group Art Unit:

1645

JUN 2 6 2002

Conf. No.:

7298

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Kathleen Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

- Information Disclosure Statement; 1.
- 2. Form PTO-1449
- 3. Copies of Cited References; and
- 4. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No. 17633/1082. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Name: Kathleen Williams Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP

111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

JUN 2 1 2002 JUN 2 1 RADEMART

Atty. Docket No.:

17633/1082

TECH CENTER 1600/2900

JUN 2 6 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Tongwen Wang

Serial No.:

09/927,738

Filed:

August 10, 2001

Entitled:

Compositions and methods for

modulating TGF-beta signaling

Examiner:

Not Yet Assigned

Group Art Unit:

1645

Conf. No.:

7298

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.82

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231.

Kathleen Williams

Name of Person Mailing Paper

Signature of Person Mailing Paper

Commissioner for Patents Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§§ 1.56, 1.97 AND 1.98

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office. A listing of the cited documents is also enclosed, as well as, for the Examiner's convenience, copies of the documents in the list. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.

Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Respectfully submitted,

Date: 6/19/62

Name: Kathleen Williams Registration No.: 34,380 Customer No.: 29933 Palmer & Dodge LLP 111 Huntington Avenue Boston, MA 02199-7613

Tel: 617-239-0100

USPTO Form 14		S. Department of Commerce	OIPE	Attorney Docket No.		TECH CENTER.1600/2900			
		DISCLOSURE STAT	EMENT 5	17633/1082			09/927,738		
I W Oldw			JIIN 2 4 2002 TO	Applicant(s):. Tong	wen Wang				
λ			7. 2002	Filing Date: Augus	t 10, 2001		Group: 1645		
U.S. PAT	ENT DO	OCUMENTS	& TRADEMARY						
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)		
	<u> </u>					<u> </u>			
FOREIGI	N PATE	NT DOCUMENTS					<u></u>		
Examiner		Document No.	Date	Country	Class	Subclass	Translation		
Initial							YES	NO	
	1	WO 98/53066	November 26, 1998	PCT	C12N	15/12	Y	<u> </u>	
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)									
	2	Abdollah, et al., "TßRI Phosphorylation of Smad2 on Ser ⁴⁶⁵ and Ser ⁴⁶⁷ Is Required for Smad2-Smad4 Complex Formation and Signaling", <i>Journal of Biological Chemistry</i> , 272, (1997): 27678-27685.							
	3	Baker, J. & Harland, R.M., "A Novel Mesoderm Inducer, Madr2, Functions in the Activin Signal Transduction Pathway", Genes and Development, 10, (1996): 1880-1889.							
	4	Chen, Y., et al., "Regulation of Transforming Growth Factor Beta- and Activin-Induced Transcription by Mammalian Mad Proteins", <i>PNAS-Proceedings of the National Academy of Sciences</i> , 93, (1996): 12992-12997.							
	5	Chen, X., et al., "Smad4 and FAST-1 in the Assembly of Activin-Responsive Factor", <i>Nature</i> , 389, (1997): 85-89.							
	6	de Caestecker, M.P., et al., "Characterization of Functional Domains within Smad4 / DPC4", Journal of Biological Chemistry, 272, (1997), 13690-13696.							
	7	Dennler, S., et al., "Direct Binding of Smad3 and Smad4 to Critical TGF-Inducible Elements in the Promoter of Human Plasminogen Activator Inhibitor-Type 1 Gene", <i>Embo Journal</i> , 17, (1998): 3091-3100.							
	8	Hata, A., et al., "Mutations Increasing Autoinhibition Inactivate Tumour Supressors Smad2 and Smad4", <i>Nature</i> , 388, (1997): 82 – 87.							
	9	Kim, J., et al., "Drosophila Mad Binds to DNA and Directly Mediates Activation of Vestigial by Decapentaplegic", <i>Nature</i> , 388, (1997): 304-308.							
	10	Kretzschmar, M., et al., "The TGF-Beta Family Mediator Smad1 is Phosphorylated Directly and Activated Functionally by the BMP Receptor Kinase", <i>Genes and Development</i> , 11, (1997): 984-995.							
	11	Lagna, G., et al., "Partnerships Between DPC4 and SMAD Proteins in TGF-Beta Signalling Pathways", <i>Nature</i> , 383, (1996): 832-836.							
	12	Liu, F., et al., "A Human Mad Protein Acting as a BMP-regulated Transcriptional Activator", <i>Nature</i> , 381, (1996) 620-623.							

01. 2	jUN 2 6 2002					
JUN 2 1 5005		TECH CENTER 1600/2900				
TRADEMAN 13	facias-Silva, M., et al., "MADR2 is a Substrate of the TGFbeta Receptor and Its Phosphorylation is equired for Nuclear Accumulation and Signaling", <i>Cell</i> , 87, (1996): 1215-1224.					
. 14	Schutte, M., et al., "DPC4 Gene in Various Tumor Types", Cano	Various Tumor Types", Cancer Research, 56, (1996): 2527-2530.				
15	Souchelnytskyi, S., et al., "Phosphorylation of Ser ⁴⁶⁵ and Ser ⁴⁶⁷ in the C Terminus of Smad2 Mediate Interaction with Smad4 and is Required for Transforming Growth Factor-Beta Signaling", <i>Journal of Biological Chemistry</i> , 272, (1997): 28107 – 28115.					
16	Yingling, J. M., et al., "Tumor Suppressor Smad4 is a Transforming Growth Factor Beta-Inducible DNA Binding Protein", <i>Molecular and Cellular Biology</i> , 17, (1997): 7019-7028.					
17	Wu, R. Y., et al., "Heteromeric and Homomeric Interactions Correlate with Signaling Activity and Functional Cooperativity of Smad3 and Smad4/DPC4", <i>Molecular and Cellular Biology</i> , 17, (1997): 2521-2528.					
18	Zawel, L., et al., "Human Smad3 and Smad4 are Sequence-Specific Transcription Activators", Molecules and Cells, 1, (1998): 611-617.					
19	Zwickl, P., et al., "Critical Elements in Proteasome Assembly", <i>Nature Structural Biology</i> , 1, (1994) 765-770.					
EXAMINER		DATE CONSIDERED				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

**Copies of references not provided at the time of this submission.